Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesDermatologyCommunity-Care beremagene geperpavec Coverage | Op…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Beremagene geperpavec (topical) for dystrophic epidermolysis bullosa — Medical Benefit Coverage Criteria

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit coverage, authorization, and quantity limits for beremagene geperpavec used to treat dystrophic epidermolysis bullosa (DEB) for members covered under the payer's medical benefit.

    Policy Summary
    PayerCommunity-Care
    PolicyBeremagene geperpavec (topical) for dystrophic epidermolysis bullosa — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewOct 1, 2025
    Next Review DateOct 1, 2025
    Key ActionObtain prior authorization with documentation of DEB diagnosis, ≥1 COL7A1 mutation, and ≥1 open DEB skin wound.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial authorization period
    1 yearcontinuation authorization period
    up to 4 vials/28 daysquantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J3401HCPCS code

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met

    Initial Approval for DEB: (i) Diagnosis of dystrophic epidermolysis bullosa; (ii) Prescribed by, or in consultation with, a dermatologist or a medical geneticist; (iii) Documentation of >= 1 mutation in the COL7A1 gene; (iv) Presence of >= 1 open dystrophic epidermolysis bullosa skin wound(s)

    Initial approval granted for six months if criteria met

    Continuation Therapy

    Covered when ALL of the following are met

    Continuation Therapy for DEB: (i) Diagnosis of dystrophic epidermolysis bullosa; (ii) Presence of >= 1 open dystrophic epidermolysis bullosa skin wound(s); (iii) Documentation of a positive clinical response as evidenced by a reduction in open dystrophic epidermolysis bullosa skin wounds

    Continuation approvals are for one year if criteria met

    The policy does not list any explicit exclusions for beremagene geperpavec in the treatment of dystrophic epidermolysis bullosa.

    The policy states that there are specific coverage criteria for initial and continuation use; therefore, failure to meet the stated criteria (for example, lack of a documented diagnosis of dystrophic epidermolysis bullosa, absence of a documented COL7A1 mutation, or no documentation of an open DEB skin wound) will render the treatment non‑covered in the absence of meeting those criteria.

    Coding and Quantity Limits

    Applicable HCPCS CodesHCPCSCovered
    J3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml
    Quantity limit: beremagene geperpavec
    Quantity limitUp to 4 vials per 28 days (1 vial = 2.5 mL)
    Per-authorization periodLimit applies to each 28-day supply period when therapy is approved
    Vial volumeEach vial contains 2.5 mL
    ProductBeremagene geperpavec topical formulation (HCPCS J3401)

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for beremagene geperpavec. Initial approvals will be issued for six months; if continued therapy is approved, subsequent authorizations will be for one year.

    • Submit prior authorization request before initiating therapy
    • Initial authorization duration: 6 months
    • Continuation authorization duration: 1 year
    Denial Risk

    Documentation-based Denials

    Failure to provide the required documentation at the time of review may result in a denial or delay of services. Ensure all supporting records requested are included with the prior authorization submission.

    • Missing genetic testing results, provider consultation notes, or wound documentation can trigger a denial

    Background

    Dystrophic epidermolysis bullosa (DEB) is an inherited blistering skin disorder identified in this policy by the requirement for a clinical diagnosis and genetic confirmation. Coverage for beremagene geperpavec is targeted to patients with a documented diagnosis of DEB, documentation of at least one COL7A1 mutation, and the presence of active open DEB skin wound(s). The policy frames therapy around wound healing response, with continuation requiring evidence of a positive clinical response as a reduction in open DEB skin wounds.

    Definitions

    Open DEB skin wound (definition)
    DefinitionPresence of ≥ 1 open dystrophic epidermolysis bullosa (DEB) skin wound(s)
    AttributionWounds must be active and attributable to dystrophic epidermolysis bullosa
    Role in criteriaRequired for both initial approval and continuation of therapy
    COL7A1 mutation (definition)
    DefinitionDocumentation of ≥ 1 mutation in the COL7A1 (collagen type VII alpha 1 chain) gene
    PurposeGenetic confirmation of dystrophic epidermolysis bullosa for eligibility
    Requirement timing
    Policy Summary
    PayerCommunity-Care
    PolicyBeremagene geperpavec (topical) for dystrophic epidermolysis bullosa — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewOct 1, 2025
    Next Review DateOct 1, 2025
    Key ActionObtain prior authorization with documentation of DEB diagnosis, ≥1 COL7A1 mutation, and ≥1 open DEB skin wound.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Quantity LimitsProvider Actions and AuthorizationBackgroundDefinitions
  1. Incomplete or absent documentation of clinical response for continuation requests may lead to denial
    2. Documentation Required

    Required Documentation for Initial Approval

    Provide complete documentation to support initial approval requests. Attach all required items in the PA submission.

    • Diagnosis of dystrophic epidermolysis bullosa (DEB)
    • Consultation or prescription from a dermatologist or medical geneticist
    • Documentation of ≥ 1 pathogenic mutation in the COL7A1 gene
    • Evidence of ≥ 1 open DEB skin wound at time of request
    Documentation Required

    Required Documentation for Continuation

    For continuation (renewal) requests, submit current evidence demonstrating ongoing need and benefit from therapy.

    • Ongoing diagnosis of dystrophic epidermolysis bullosa
    • Documentation of ≥ 1 open DEB skin wound at the time of renewal
    • Objective evidence of positive clinical response (e.g., reduction in number or size of open DEB wounds, photographic documentation, wound assessment notes)
    Required for initial approval; referenced in continuation criteria as part of diagnosis confirmation